Pacira Pharma (PCRX) Misses Q2 EPS by 35c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.53, $0.35 worse than the analyst estimate of $0.88. Revenue for the quarter came in at $169.4 million versus the consensus estimate of $172.22 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• FactSet Research Systems (FDS) PT Raised to $253 at Jefferies
• General Mills (GIS) PT Lowered to $42 at Freedom Broker